Aileron Therapeutics (NASDAQ:ALRN) Issues Earnings Results, Misses Estimates By $0.72 EPS

Aileron Therapeutics (NASDAQ:ALRN) posted its quarterly earnings results on Monday. The company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.72), Zacks reports.

Aileron Therapeutics Stock Performance

NASDAQ:ALRN traded down $0.09 during trading hours on Wednesday, reaching $3.68. The stock had a trading volume of 12,144 shares, compared to its average volume of 73,783. Aileron Therapeutics has a 52 week low of $1.01 and a 52 week high of $7.42. The company has a 50 day moving average price of $5.04 and a two-hundred day moving average price of $4.09. The stock has a market capitalization of $79.45 million, a PE ratio of -1.16 and a beta of 2.32.

Wall Street Analyst Weigh In

Separately, LADENBURG THALM/SH SH boosted their price target on Aileron Therapeutics from $9.00 to $19.00 and gave the stock a “buy” rating in a report on Thursday, April 18th.

Insiders Place Their Bets

In other news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total transaction of $85,526.15. Following the transaction, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. In other news, major shareholder Of Texas/Texas Am I. University sold 20,315 shares of the business’s stock in a transaction that occurred on Wednesday, May 1st. The stock was sold at an average price of $4.21, for a total transaction of $85,526.15. Following the transaction, the insider now owns 1,779,306 shares of the company’s stock, valued at approximately $7,490,878.26. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, major shareholder Of Texas/Texas Am I. University sold 10,746 shares of the business’s stock in a transaction that occurred on Monday, April 29th. The shares were sold at an average price of $4.95, for a total value of $53,192.70. Following the transaction, the insider now directly owns 1,799,711 shares in the company, valued at approximately $8,908,569.45. The disclosure for this sale can be found here. Corporate insiders own 5.57% of the company’s stock.

About Aileron Therapeutics

Aileron Therapeutics, Inc operates as a clinical stage chemoprotection oncology company in the United States. The company is developing ALRN-6924, which is in Phase 1 trial for solid tumor and lymphoma; Phase 2a clinical trial to treat peripheral T-cell lymphoma; Phase I clinical trial for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); Phase 1b trial to test the combination of ALRN-6924 and cytarabine, or Ara-C, in patients with MDS; and a Phase 2a combination trial of ALRN-6924 and palbociclib in patients with tumors harboring MDM2 amplifications co-amplifications, as well as for patients with p53-mutated small cell lung cancer that has completed Phase 1b clinical trial.